Investment Thesis
Pliant Therapeutics is a pre-commercial stage pharmaceutical company with zero revenue and approximately 4-5 months of cash runway at current $128.3M annual burn rates, creating critical near-term capital requirement risk. While year-over-year loss improvements (29% better net income, 30% better EPS) and zero debt demonstrate operational progress, the fundamental mismatch between $45.4M cash reserves and accelerating burn rate necessitates an urgent capital raise with significant dilution risk to existing shareholders.
Strengths
- Net loss and EPS improving year-over-year indicating operational efficiency gains or reduced spend
- Zero long-term debt and strong relative balance sheet with $181.2M stockholders equity and no leverage
- Exceptional short-term liquidity with 12.0x current and quick ratios providing flexibility for near-term obligations
Risks
- Zero revenue indicating pre-commercial stage with binary outcome risk dependent entirely on clinical/regulatory success
- Critical cash runway of only 4-5 months at current burn rate requiring dilutive capital raise within quarters
- Substantial operating cash burn of $128.3M annually against limited assets, indicating unsustainable burn trajectory without revenue inflection
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash position relative to operating runway
- Clinical trial advancement, regulatory milestone achievements, and potential commercialization timelines
- Capital raise announcements, financing terms, and shareholder dilution from equity issuance
Financial Metrics
Revenue
0.0
Net Income
-149.3M
EPS (Diluted)
$-2.43
Free Cash Flow
-128.7M
Total Assets
225.2M
Cash
45.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-82.4%
ROA
-66.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
12.00x
Quick Ratio
12.00x
Debt/Equity
0.00x
Debt/Assets
19.5%
Interest Coverage
-351.40x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T09:30:31.420033 |
Data as of: 2025-12-31 |
Powered by Claude AI